Latest Insights

Can biotech bounce back?

Can biotech bounce back?

Biotechnology stocks have been suffering a decline for some months. But while the sector faces some challenges, attractive valuations and a rapid pace of medical innovation could become difficult for investors to ignore, says Portfolio Manager Andy Acker.

A hawkish rate cut
Quick Views Interest Rates

A hawkish rate cut

A pause after October’s rate cut in the US may make sense in the short term, but greater accommodation may be necessary over the long haul.

High yield: blurred lines in valuations create opportunities

High yield: blurred lines in valuations create opportunities

In this video update, Tom Ross, corporate credit portfolio manager, looks at conditions in the high yield bond market, exploring how technical conditions, dispersion among credits and blurred lines in valuations are creating opportunities.


Hunt opportunity closer to home

Janus Henderson Asian Equities

Janus Henderson offers six different ways investors may capitalise on Asia’s rise and earn their stripes.


Global Life Sciences Fund

By understanding the science and business of health care, the strategy invests in companies addressing unmet medical needs or improving health care efficiencies.

Balanced Fund

For over 20 years, this dynamic allocation strategy has delivered our equity and fixed income expertise in a one-stop core solution.

Horizon Global Technology Fund

Aims to generate long-term capital growth through investment in a globally diversified portfolio of technology-related companies.

Subscribe for relevant insights delivered straight to your inbox